title: The PROGRESS trial three years later: time for more action, less distraction.
authors.affiliation: The George Institute for International Health, University of Sydney, PO Box M201, Sydney, NSW 2050, Australia.
authors.forename: Stephen
authors.initials: S
authors.lastname: Macmahon
authors.forename: Bruce
authors.initials: B
authors.lastname: Neal
authors.forename: Anthony
authors.initials: A
authors.lastname: Rodgers
authors.forename: John
authors.initials: J
authors.lastname: Chalmers
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007190:Indapamide / Q000627:therapeutic use*; D020913:Perindopril / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007190:Indapamide; D020913:Perindopril